South African authorities are investigating Johnson & Johnson and its Janssen subsidiary over “excessive pricing” of a lifesaving tuberculosis drug, the latest imbroglio to engulf the company over its medicine.
In a brief statement, the South African Competition Commission confirmed that it lodged a complaint earlier this week against the health care giant over its TB medicine, bedaquiline, which is also sold under the Sirturo brand name. The regulator did not provide any details other than to say it has information suggesting a “reasonable suspicion” the company may also have engaged in “exclusionary practices.”
We asked J&J for comment and will update you accordingly.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.